Cancer Treatment Centers of America

Recent papers from Cancer Treatment Centers of America

1. Independent Cancer Research in Low- and Middle-Income Countries: Why it matters and how to build itThe Oncologist · 2026
2. Impact of Assertive Outreach, Individual Involvement, and Significant Other Involvement on XR-NTX AdherenceSubstance Use &amp Addiction Journal · 2026
3. BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 × VEGF bsAb) in patients with advanced solid tumors.Journal of Clinical Oncology · 2026
4. Real‐world use of lecanemab: patient pathway findings from a US multicenter studyAlzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2026
5. Abstract 3911: Use of ALK inhibitors in patients with non-lung malignancies bearing ALK alteration prolongs treatment duration.Cancer Research · 2026
6. Patient Characteristics Associated with Successful Initiation of Extended-Release Naltrexone in the X:BOT TrialSubstance Use & Misuse · 2026
7. 410P Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase III ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)ESMO Open · 2026
8. Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant TherapyCancers · 2026
9. Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitorsHaematologica · 2026
10. Arrhythmias across the tree of life: comparative insights for human electrophysiologyFrontiers in Cardiovascular Medicine · 2026
11. Practice Patterns and Outcomes in Advanced Colorectal Cancers From a Multi-Institutional Analysis: Real-World Evidence From IndiaJCO Global Oncology · 2025
12. Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 studyEuropean Journal of Cancer · 2025
13. Breastfeeding attributable fraction of triple negative breast cancer in the USnpj Breast Cancer · 2025
14. Scaling new heights: a pilot study of the impact of climbing on balance, agility, and dexterity in individuals with Parkinson’s diseaseArchives of Physiotherapy · 2025
15. A Naturalistic Study of Individuals Involved in the Justice System Who Experienced Both Formulations of Extended-release BuprenorphineJournal of Addiction Medicine · 2025
16. Cancer-associated fibroblasts maintain critical pancreatic cancer cell lipid homeostasis in the tumor microenvironmentCell Reports · 2024
17. Real-time non-invasive control of ultrasound hyperthermia using high-frequency ultrasonic backscattered energy in ex vivo tissue and in vivo animal studiesPhysics in Medicine and Biology · 2024
18. Gefapixant as a P2X3 receptor antagonist treatment for obstructive sleep apnea: a randomized controlled trialJournal of Clinical Sleep Medicine · 2024
19. Integrated genomic and transcriptomic characterization of neuroendocrine carcinomas for improved treatment decision-making.Journal of Clinical Oncology · 2024
20. Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket TrialClinical Cancer Research · 2024